In order to explore the application value of DCE-MRI in clinical diagnosis and treatment, guide early clinical diagnosis, evaluate prognosis, guide clinical selection of treatment options and improve medical level, the expression of adenocarcinoma, its relationship with clinicopathology, and the significance of co-expression of the proliferating cell nuclear antigen (PCNA), Ki67 protein and cyclooxygenase 2 (COX-2) in breast cancer are analyzed.
CEUS with VEGFR2-targeted microbubbles allowed for monitoring regorafenib functional and molecular therapy effects on experimental colorectal adenocarcinomas with a significant decline of CEUS and DCE-MRI perfusion parameters as well as a significant reduction of specifically bound microbubbles under therapy, consistent with a reduced expression of VEGFR2.